282 related articles for article (PubMed ID: 26230099)
41. Impact of Antibiotic-Resistant Bacteria on Immune Activation and Clostridioides difficile Infection in the Mouse Intestine.
Keith JW; Dong Q; Sorbara MT; Becattini S; Sia JK; Gjonbalaj M; Seok R; Leiner IM; Littmann ER; Pamer EG
Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31907198
[TBL] [Abstract][Full Text] [Related]
42. Role of leptin-mediated colonic inflammation in defense against Clostridium difficile colitis.
Madan R; Guo X; Naylor C; Buonomo EL; Mackay D; Noor Z; Concannon P; Scully KW; Pramoonjago P; Kolling GL; Warren CA; Duggal P; Petri WA
Infect Immun; 2014 Jan; 82(1):341-9. PubMed ID: 24166957
[TBL] [Abstract][Full Text] [Related]
43. New perspectives in Clostridium difficile disease pathogenesis.
Monaghan TM
Infect Dis Clin North Am; 2015 Mar; 29(1):1-11. PubMed ID: 25573674
[TBL] [Abstract][Full Text] [Related]
44. Microbiota in vitro modulated with polyphenols shows decreased colonization resistance against Clostridioides difficile but can neutralize cytotoxicity.
Mahnic A; Auchtung JM; Poklar Ulrih N; Britton RA; Rupnik M
Sci Rep; 2020 May; 10(1):8358. PubMed ID: 32433519
[TBL] [Abstract][Full Text] [Related]
45. Clostridium difficile Infection: A Model for Disruption of the Gut Microbiota Equilibrium.
Blanchi J; Goret J; Mégraud F
Dig Dis; 2016; 34(3):217-20. PubMed ID: 27028327
[TBL] [Abstract][Full Text] [Related]
46. Type 3 Immunity during Clostridioides difficile Infection: Too Much of a Good Thing?
Saleh MM; Petri WA
Infect Immun; 2019 Dec; 88(1):. PubMed ID: 31570564
[No Abstract] [Full Text] [Related]
47.
Battaglioli EJ; Hale VL; Chen J; Jeraldo P; Ruiz-Mojica C; Schmidt BA; Rekdal VM; Till LM; Huq L; Smits SA; Moor WJ; Jones-Hall Y; Smyrk T; Khanna S; Pardi DS; Grover M; Patel R; Chia N; Nelson H; Sonnenburg JL; Farrugia G; Kashyap PC
Sci Transl Med; 2018 Oct; 10(464):. PubMed ID: 30355801
[TBL] [Abstract][Full Text] [Related]
48. Fecal Microbial Transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent Clostridium difficile infection patients.
Bruno G; Gagliardi A; Oliva A; Trancassini M; Macone A; Cicerone C; D'Abramo A; Iebba V; Auria S; Bonfiglio G; Zingaropoli MA; D'Ettorre G; Badiali D; Vullo V; Corazziari ES; Schippa S
New Microbiol; 2019 Oct; 42(4):221-224. PubMed ID: 31609455
[TBL] [Abstract][Full Text] [Related]
49. Faecalibacterium prausnitzii and a Prebiotic Protect Intestinal Health in a Mouse Model of Antibiotic and Clostridium difficile Exposure.
Roychowdhury S; Cadnum J; Glueck B; Obrenovich M; Donskey C; Cresci GAM
JPEN J Parenter Enteral Nutr; 2018 Sep; 42(7):1156-1167. PubMed ID: 29385239
[TBL] [Abstract][Full Text] [Related]
50.
Mileto SJ; Jardé T; Childress KO; Jensen JL; Rogers AP; Kerr G; Hutton ML; Sheedlo MJ; Bloch SC; Shupe JA; Horvay K; Flores T; Engel R; Wilkins S; McMurrick PJ; Lacy DB; Abud HE; Lyras D
Proc Natl Acad Sci U S A; 2020 Apr; 117(14):8064-8073. PubMed ID: 32198200
[TBL] [Abstract][Full Text] [Related]
51. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
[TBL] [Abstract][Full Text] [Related]
52. Prevention and treatment of
Eliakim-Raz N; Bishara J
Hum Vaccin Immunother; 2019; 15(6):1453-1456. PubMed ID: 29781761
[TBL] [Abstract][Full Text] [Related]
53. Recent developments in the management of recurrent Clostridioides difficile infection.
Mendo-Lopez R; Villafuerte-Gálvez J; White N; Mahoney MV; Kelly CP; Alonso CD
Anaerobe; 2020 Apr; 62():102108. PubMed ID: 31606481
[TBL] [Abstract][Full Text] [Related]
54. Clostridium difficile modulates host innate immunity via toxin-independent and dependent mechanism(s).
Jafari NV; Kuehne SA; Bryant CE; Elawad M; Wren BW; Minton NP; Allan E; Bajaj-Elliott M
PLoS One; 2013; 8(7):e69846. PubMed ID: 23922820
[TBL] [Abstract][Full Text] [Related]
55. The Role of the Gut Microbiome in Cancer: A Review, With Special Focus on Colorectal Neoplasia and Clostridioides difficile.
Anderson SM; Sears CL
Clin Infect Dis; 2023 Dec; 77(Suppl 6):S471-S478. PubMed ID: 38051969
[TBL] [Abstract][Full Text] [Related]
56. The Proton Pump Inhibitor Omeprazole Does Not Promote Clostridioides difficile Colonization in a Murine Model.
Tomkovich S; Lesniak NA; Li Y; Bishop L; Fitzgerald MJ; Schloss PD
mSphere; 2019 Nov; 4(6):. PubMed ID: 31748246
[TBL] [Abstract][Full Text] [Related]
57. Microbiologic factors affecting Clostridium difficile recurrence.
Chilton CH; Pickering DS; Freeman J
Clin Microbiol Infect; 2018 May; 24(5):476-482. PubMed ID: 29208562
[TBL] [Abstract][Full Text] [Related]
58. A modified R-type bacteriocin specifically targeting Clostridium difficile prevents colonization of mice without affecting gut microbiota diversity.
Gebhart D; Lok S; Clare S; Tomas M; Stares M; Scholl D; Donskey CJ; Lawley TD; Govoni GR
mBio; 2015 Mar; 6(2):. PubMed ID: 25805733
[TBL] [Abstract][Full Text] [Related]
59. Nonantimicrobial drug targets for Clostridium difficile infections.
Darkoh C; Deaton M; DuPont HL
Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
[TBL] [Abstract][Full Text] [Related]
60. Rapid change of fecal microbiome and disappearance of Clostridium difficile in a colonized infant after transition from breast milk to cow milk.
Davis MY; Zhang H; Brannan LE; Carman RJ; Boone JH
Microbiome; 2016 Oct; 4(1):53. PubMed ID: 27717398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
